Ian Krop
MD PhD
Professor
👥Biography 个人简介
Ian Krop at Yale contributed to the clinical development of T-DM1 (trastuzumab emtansine) — the first approved ADC for HER2-positive breast cancer — including the EMILIA and TH3RESA trials. His subsequent work on T-DXd compared to T-DM1 (DESTINY-Breast03 showing T-DXd superiority) and on mechanisms of HER2 ADC resistance has contributed to the evolution of HER2-directed ADC therapy in breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ian Krop 的研究动态
Follow Ian Krop's research updates
留下邮箱，当我们发布与 Ian Krop（Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment